Skip to main content
Clinical Trials/NCT02113865
NCT02113865
Completed
Not Applicable

Obtención de un Panel de puntuación ("Score System") Para la predicción de Riesgo Individualizado y la detección Precoz de Carcinoma Hepatocelular (HCC) en Sujetos Coinfectados VIH/VHC

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acquired Immunodeficiency Syndrome Virus
Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Enrollment
45
Locations
1
Primary Endpoint
Sera inflammatory markers
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The aim of this study is to establish a clinical score panel based on clinical, molecular and genetic parameters that allow us to stratify and obtain an early detection of patients with an increased risk of developing hepatocellular carcinoma (HCC).

Detailed Description

Transversal study design like a "proof of concept". Primary objective: The main objective is try to stablish a descriptive panel (first phase of a score system) based in the conjunction or sum of several clinical and laboratory parameters (molecular and genetic factors). The aim is to detect in a fast, early and successful way those patients that presents a high risk to develop an hepatocellular carcinoma (HCC) in the future in a specific population: HIV and HCV coinfected patients. The establishment of this panel will allow clinicians set up a correct treatment decreasing the probability of liver cirrhosis and HCC.

Registry
clinicaltrials.gov
Start Date
October 2013
End Date
February 2015
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Human immunodeficiency virus chronic infection
  • Hepatitis C virus chronic infection
  • No other liver viral coinfections

Exclusion Criteria

  • Alcohol consume
  • Immunosuppressor or immunoactive treatment

Outcomes

Primary Outcomes

Sera inflammatory markers

Time Frame: 1 day (Routine visit to normal following in Infectious Disease Department)

Inflammatory markers will be measure used a Enzyme-linked Immunosorbent Assay

Secondary Outcomes

  • Sera apoptotic markers(1 day (Routine visit in disease following at Infectious Disease Department))

Study Sites (1)

Loading locations...

Similar Trials